Research Analysts Issue Forecasts for TARS Q2 Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Investment analysts at HC Wainwright issued their Q2 2025 EPS estimates for Tarsus Pharmaceuticals in a research note issued on Tuesday, May 27th. HC Wainwright analyst M. Caufield forecasts that the company will earn ($0.41) per share for the quarter. HC Wainwright has a “Buy” rating and a $72.00 price target on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals’ Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($1.60) EPS, FY2026 earnings at ($2.10) EPS, FY2027 earnings at $0.76 EPS, FY2028 earnings at $0.44 EPS and FY2029 earnings at $0.89 EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The business had revenue of $78.34 million during the quarter, compared to analyst estimates of $72.50 million.

Other equities research analysts have also recently issued reports about the stock. Jefferies Financial Group boosted their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. The Goldman Sachs Group lifted their target price on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a “neutral” rating in a report on Monday, May 5th. Guggenheim increased their target price on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a “buy” rating in a research report on Friday, May 2nd. Barclays cut their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Finally, Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 22nd. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $66.17.

Tarsus Pharmaceuticals Trading Down 1.2%

Shares of NASDAQ TARS opened at $42.94 on Thursday. The company’s fifty day moving average is $46.93 and its 200-day moving average is $48.92. The stock has a market cap of $1.80 billion, a price-to-earnings ratio of -11.27 and a beta of 0.94. Tarsus Pharmaceuticals has a twelve month low of $20.08 and a twelve month high of $57.28. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Jennison Associates LLC increased its holdings in Tarsus Pharmaceuticals by 14.8% during the fourth quarter. Jennison Associates LLC now owns 2,500,132 shares of the company’s stock worth $138,432,000 after buying an additional 321,552 shares during the last quarter. Barclays PLC grew its stake in Tarsus Pharmaceuticals by 345.9% during the third quarter. Barclays PLC now owns 98,663 shares of the company’s stock valued at $3,246,000 after acquiring an additional 76,538 shares in the last quarter. Northern Trust Corp grew its stake in Tarsus Pharmaceuticals by 12.6% during the fourth quarter. Northern Trust Corp now owns 357,616 shares of the company’s stock valued at $19,801,000 after acquiring an additional 40,061 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Tarsus Pharmaceuticals in the 4th quarter worth approximately $1,107,000. Finally, Bleakley Financial Group LLC purchased a new position in Tarsus Pharmaceuticals in the 4th quarter worth approximately $323,000. 90.01% of the stock is owned by institutional investors.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, General Counsel Bryan Wahl sold 3,341 shares of the firm’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $154,654.89. Following the completion of the sale, the general counsel now directly owns 58,057 shares in the company, valued at approximately $2,687,458.53. This trade represents a 5.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Dianne C. Whitfield sold 2,315 shares of the firm’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $107,161.35. Following the completion of the transaction, the insider now directly owns 50,751 shares in the company, valued at $2,349,263.79. This trade represents a 4.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,542 shares of company stock worth $1,581,173. 8.25% of the stock is currently owned by company insiders.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.